Literature DB >> 33663440

A surrogate measure for patient reported symptom remission in administrative data.

Farrokh Alemi1, Mai Aljuaid2, Naren Durbha2, Melanie Yousefi3, Hua Min2, Louisa G Sylvia4,5, Andrew A Nierenberg4,5.   

Abstract

BACKGROUND: In real-world pragmatic administrative databases, patient reported remission is often missing.
OBJECTIVE: We evaluate if, in administrative data, five features of antidepressant use patterns can replace patient-reported symptom remission.
METHOD: We re-examined data from Sequence Treatment Alternatives to Relieve Depression (STAR*D) study. Remission was measured using 50% reduction in Hamilton index. Pattern of antidepressant use was examined through five variables: (a) number of prior ineffective antidepressants, (b) duration of taking current antidepressant, (c) receiving therapeutic dose of the medication, and (d) switching to another medication, or (e) augmenting with another antidepressant. The likelihood ratio (LR) associated with each of these predictors was assessed in 90% of data (3329 cases) and evaluated in 10% of data (350 cases) set-aside for evaluation. The accuracy of predictions was calculated using Area under the Receiver Operating Curve (AROC).
RESULTS: Patients who took antidepressants for 14 weeks (LR = 2.007) were more likely to have symptom remission. Prior use of 3 antidepressants reduced the odds of remission (LR = 0.771). Patients who received antidepressants below therapeutic dose were 5 times less likely to experience remission (LR = 0.204). Antidepressant that were augment or switched, almost never led to remission (LR = 0.008, LR = 0.002 respectively). Patterns of antidepressant use accurately (AROC = 0.93) predicted symptom remission.
CONCLUSION: Within the first 100 days, antidepressants use patterns could serve as a surrogate measure for patient-reported remission of symptoms.

Entities:  

Keywords:  Antidepressant effectiveness; Medication augmentation; Medication switch; Prior medication use; STAR*D; Symptom remission; Therapeutic dose

Year:  2021        PMID: 33663440      PMCID: PMC7931356          DOI: 10.1186/s12888-021-03133-1

Source DB:  PubMed          Journal:  BMC Psychiatry        ISSN: 1471-244X            Impact factor:   3.630


  24 in total

1.  A comparison of observational studies and randomized, controlled trials.

Authors:  K Benson; A J Hartz
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

2.  Late-life depression and the association with multimorbidity and polypharmacy: a cross-sectional study.

Authors:  Floor Holvast; Bernard A van Hattem; Judith Sinnige; François Schellevis; Katja Taxis; Huibert Burger; Peter F M Verhaak
Journal:  Fam Pract       Date:  2017-09-01       Impact factor: 2.267

Review 3.  Evidence-based pharmacotherapy of treatment-resistant unipolar depression.

Authors:  Markus Dold; Siegfried Kasper
Journal:  Int J Psychiatry Clin Pract       Date:  2016-11-16       Impact factor: 1.812

4.  Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

Authors:  Roy H Perlis; Michael J Ostacher; Jayendra K Patel; Lauren B Marangell; Hongwei Zhang; Stephen R Wisniewski; Terence A Ketter; David J Miklowitz; Michael W Otto; Laszlo Gyulai; Noreen A Reilly-Harrington; Andrew A Nierenberg; Gary S Sachs; Michael E Thase
Journal:  Am J Psychiatry       Date:  2006-02       Impact factor: 18.112

5.  Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design.

Authors:  A John Rush; M Lynn Crismon; T Michael Kashner; Marcia G Toprac; Thomas J Carmody; Madhukar H Trivedi; Trisha Suppes; Alexander L Miller; Melanie M Biggs; Kathy Shores-Wilson; Bradley P Witte; Steven P Shon; William V Rago; Kenneth Z Altshuler
Journal:  J Clin Psychiatry       Date:  2003-04       Impact factor: 4.384

6.  Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study.

Authors:  Heather D Anderson; Wilson D Pace; Anne M Libby; David R West; Robert J Valuck
Journal:  Clin Ther       Date:  2011-12-16       Impact factor: 3.393

7.  Understanding the severity of depression: Which symptoms of depression are the best indicators of depression severity?

Authors:  Mark Zimmerman; Caroline Balling; Iwona Chelminski; Kristy Dalrymple
Journal:  Compr Psychiatry       Date:  2018-09-24       Impact factor: 3.735

8.  Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project.

Authors:  Madhukar H Trivedi; A John Rush; M Lynn Crismon; T Michael Kashner; Marcia G Toprac; Thomas J Carmody; Tracie Key; Melanie M Biggs; Kathy Shores-Wilson; Bradley Witte; Trisha Suppes; Alexander L Miller; Kenneth Z Altshuler; Steven P Shon
Journal:  Arch Gen Psychiatry       Date:  2004-07

9.  Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.

Authors:  A John Rush; Maurizio Fava; Stephen R Wisniewski; Philip W Lavori; Madhukar H Trivedi; Harold A Sackeim; Michael E Thase; Andrew A Nierenberg; Frederic M Quitkin; T Michael Kashner; David J Kupfer; Jerrold F Rosenbaum; Jonathan Alpert; Jonathan W Stewart; Patrick J McGrath; Melanie M Biggs; Kathy Shores-Wilson; Barry D Lebowitz; Louise Ritz; George Niederehe
Journal:  Control Clin Trials       Date:  2004-02

10.  Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data.

Authors:  Julie C Locklear; Berhanu Alemayehu; Robert S Brody; Soheil Chavoshi; Ozgur Tunceli; David Kern; Willie R Earley
Journal:  Clin Ther       Date:  2013-11-22       Impact factor: 3.393

View more
  1 in total

1.  Effectiveness of common antidepressants: a post market release study.

Authors:  Farrokh Alemi; Hua Min; Melanie Yousefi; Laura K Becker; Christopher A Hane; Vijay S Nori; Janusz Wojtusiak
Journal:  EClinicalMedicine       Date:  2021-10-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.